

17 | Astellas

3-11, Nihonbashi-honcho 2-chome, Chuo-ku Tokyo 103-8411 (Japan)
Tel: (81) 3 3244 3000 Fax: (81) 3 3244 3272
www.astellas.com

| | |
|-------------------------|--------------|
| HEADCOUNT | 13,900 |
| YEAR ESTABLISHED | 2005 |
| PHARMA REVENUES | \$7,862 +2% |
| TOTAL REVENUES | \$7,881 +1% |
| NET INCOME | \$1,124 +23% |
| R&D BUDGET | \$1,438 +14% |

DRUGS APPROVED/LAUNCHED

| <i>Drug</i> | <i>Indication</i> |
|-------------|--|
| vaprisol | euvolemic hyponatremia |
| advagraf | prevention of organ rejection (EU) |
| prograf | prevention of organ rejection |
| celecoxib | rheumatoid arthritis and osteoarthritis pain |

DRUGS PENDING APPROVAL

| <i>Drug</i> | <i>Indication</i> |
|-------------|--------------------------------|
| tacrolimus | lupus nephritis |
| ramosetron | irritable bowel syndrome |
| nateglinide | type 2 diabetes |
| micafungin | fungal infection |
| tacrolimus | suppression of organ rejection |
| garenoxacin | respiratory infections |
| telmisartan | type 2 diabetes |
| minodronate | osteoporosis |
| canivaptan | hypervolemic hyponatremia |

DRUGS IN PHASE IIB AND BEYOND

| <i>Drug</i> | <i>Indication</i> |
|-------------|------------------------|
| ym060 | IBS |
| ym150 | venous thromboembolism |

| | |
|-----------------------|---|
| tamsulosin | lower urinary tract syndrome, pediatric neurogenic bladder |
| interferon alfacon -1 | chronic hepatitis C virus |
| nateglinide | type 2 diabetes |
| celecoxib | post surgical pain |
| tacrolimus | ulcerative colitis, myasthenia gravis, atopic dermatitis, psoriasis |
| famotidine | gastro-esophageal reflux disease |
| zolpidem | insomnia |
| valdecoxib | rheumatoid arthritis, osteoarthritis, back pain |
| beraprost | chronic renal failure |
| telavancin | complicated skin and skin structure infections, hospital acquired pneumonia |

TOP SELLING DRUGS

| <i>Drug</i> | <i>Indication</i> | <i>\$</i> | <i>(+/- %)</i> |
|-----------------|-------------------|-----------|----------------|
| prograf | transplantation | \$1,501 | 16% |
| harnal | BPH | \$1,087 | -11% |
| lipitor (Japan) | cholesterol | \$811 | 0% |
| vesicare | bladder | \$310 | 137% |

Account for 47% of total pharma sales, up from 45% in 2005.

18 | Daiichi-Sankyo

3-5-1 Nihombashi-honcho, Chuo-ku, Tokyo, 103-8426 (Japan)
Tel: (81) 3 6255 1111 Fax: (81) 3 5255 7035
www.daiichisankyo.co.jp

| | |
|-------------------------|-------------|
| HEADCOUNT | 18,434 |
| YEAR ESTABLISHED | 2005 |
| PHARMA REVENUES | \$7,166 +3% |
| TOTAL REVENUES | \$7,957 -3% |
| NET INCOME | \$672 -13% |
| R&D BUDGET | \$1,460 +4% |

DRUGS PENDING APPROVAL

| <i>Drug</i> | <i>Indication</i> |
|-------------------|-------------------|
| welchol | type 2 diabetes |
| benicar + norvasc | hypertension |

DRUGS IN PHASE IIB AND BEYOND

| <i>Drug</i> | <i>Indication</i> |
|-------------|-------------------------|
| cs-747 | oral antiplatelet agent |
| colesevelam | diabetes |
| cs-8663 | hypertension |
| cs-011 | diabetes |

EARLY RESEARCH PROJECTS

| <i>Drug</i> | <i>Indication</i> |
|-------------|-------------------|
| cs-3030 | anticoagulant |

| | |
|---------|-------------------|
| da-697b | anti-platelet |
| cs-7017 | cancer |
| cs-1008 | cancer |
| cs-0777 | immunosuppression |

DRUGS COMING OFF PATENT

| <i>Drug</i> | <i>Indication</i> |
|-------------|---------------------------------|
| pravastatin | antihyperlipidemic agent (2006) |

TOP SELLING DRUGS

| <i>Drug</i> | <i>Indication</i> | <i>\$</i> | <i>(+/- %)</i> |
|--------------|-------------------|-----------|----------------|
| olmesartan | hypertension | \$1,372 | 68% |
| levofloxacin | anti-infection | \$891 | -1% |
| pravastatin | cholesterol | \$800 | -37% |

Account for 43% of total pharma sales, same as in 2005.